This document provides general recommendations for antihyperglycemic therapy in type 2 diabetes from the American Diabetes Association. It discusses glycemic targets based on results from the Diabetes Control and Complications Trial and efficacy categories of antihyperglycemic drug classes based on their ability to lower A1C. It also recommends considering low-dose aspirin therapy for primary prevention in those with type 2 diabetes at increased cardiovascular risk and for secondary prevention in those with a history of CVD.
This document provides general recommendations for antihyperglycemic therapy in type 2 diabetes from the American Diabetes Association. It discusses glycemic targets based on results from the Diabetes Control and Complications Trial and efficacy categories of antihyperglycemic drug classes based on their ability to lower A1C. It also recommends considering low-dose aspirin therapy for primary prevention in those with type 2 diabetes at increased cardiovascular risk and for secondary prevention in those with a history of CVD.
This document provides general recommendations for antihyperglycemic therapy in type 2 diabetes from the American Diabetes Association. It discusses glycemic targets based on results from the Diabetes Control and Complications Trial and efficacy categories of antihyperglycemic drug classes based on their ability to lower A1C. It also recommends considering low-dose aspirin therapy for primary prevention in those with type 2 diabetes at increased cardiovascular risk and for secondary prevention in those with a history of CVD.
Diabetes Care 2018 Diabetes Control and Complications Trial (DCCT) Oral glucose tolerance test (OGTT) Fasting plasma glucose (FPG) plasma glucose (PG) National Glycohemoglobin Standardization Program (NGSP) Glycemic Targets efficacy of the antihyperglycemic drug classes
Mean HbA1c reduction Efficacy category
Potential of >2% (>22 mmol/mol) Very high >1–2% (>11–22 mmol/mol) High >0.5–1% (>5.5–11 mmol/mol) Intermediate ≤0.5% (≤5.5 mmol/mol) Low ANTIPLATELET AGENTS
➢Consider aspirin therapy (75–162 mg/day) as a primary
prevention strategy in those with type 1 or type 2 diabetes who are at increased cardiovascular risk. This includes most men or women aged >=50 years who have at least one additional major risk factor (family history of ASCVD, hypertension, smoking, dyslipidemia, or albuminuria) and are not at increased risk of bleeding
➢Use aspirin therapy (75–162mg/day) as a secondary prevention
strategy in those with diabetes and a history of atherosclerotic CVD